125 related articles for article (PubMed ID: 3912620)
1. Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result.
Hubay CA; Pearson OH; Manni A; Gordon NH; McGuire WL
J Steroid Biochem; 1985 Dec; 23(6B):1147-50. PubMed ID: 3912620
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.
Pearson OH; Hubay CA; Marshall JS; Gordon NH; McGuire WL; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C
Breast Cancer Res Treat; 1983; 3 Suppl():S61-8. PubMed ID: 6367862
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report.
Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Surgery; 1980 May; 87(5):494-501. PubMed ID: 7368100
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer.
Wallgren A; Baral E; Glas U; Karnström L; Nordenskiöld B; Theve NO; Silfverswärd C
J Steroid Biochem; 1985 Dec; 23(6B):1161-2. PubMed ID: 3912623
[TBL] [Abstract][Full Text] [Related]
6. Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapy.
Crowe JP; Gordon NH; Antunez AR; Hubay CA; Pearson OH; Marshall JS; McGuire WL
Surgery; 1987 Oct; 102(4):622-7. PubMed ID: 3310297
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial.
Hubay CA; Pearson OH; Marshall JS; Rhodes RS; DeBanne SM; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Cancer; 1980 Dec; 46(12 Suppl):2805-8. PubMed ID: 7004624
[TBL] [Abstract][Full Text] [Related]
8. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
9. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment in operable breast cancer.
Goldhirsch A
J Steroid Biochem; 1985 Dec; 23(6B):1155-60. PubMed ID: 3912622
[TBL] [Abstract][Full Text] [Related]
12. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ
J Steroid Biochem; 1985 Dec; 23(6B):1151-4. PubMed ID: 3912621
[TBL] [Abstract][Full Text] [Related]
14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
15. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
16. Short-term tamoxifen plus chemotherapy: superior results in node-positive breast cancer.
Crowe JP; Gordon NH; Shenk RR; Soegiarso RW; Hubay CA; Mansour EG; Shuck JM; Pearson OH; Marshall JS; Arafah B
Surgery; 1990 Oct; 108(4):619-27; discussion 627-8. PubMed ID: 2218871
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial.
Hubay CA; Pearson OH; Marshall JS; Stellato TA; Rhodes RS; DeBanne SM; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Breast Cancer Res Treat; 1981; 1(1):77-82. PubMed ID: 6756509
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
Bezwoda WR; Derman D; De Moor NG; Lange M; Levin J
Cancer; 1982 Dec; 50(12):2747-50. PubMed ID: 6754067
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
20. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
